2018 SEP 27 AM 9:42
OFFICE OF THE SECRETARY

MURIEL BOWSER
MAYOR

SEP 27 2018

The Honorable Phil Mendelson
Chairman
Council of the District of Columbia
1350 Pennsylvania Avenue, NW, Suite 504
Washington, D.C. 20004

Dear Chairman Mendelson:

Enclosed for consideration and approval by the Council of the District of Columbia is a bill entitled the "Synthetics Abatement and Full Enforcement Drug Control Amendment Act of 2018," and the accompanying emergency declaration, temporary, and permanent versions.

The existing drug classification system has made it difficult to make arrests and move forward with prosecutions for crimes related to the production and sale of synthetic drugs, such as synthetic cannabinoids and synthetic opioids. The District has seen a recent and sustained spike in the number of overdoses caused by these synthetic drugs. According to Fire and Emergency Medical Services (FEMS), from April 1, 2018 through September 23, 2018, FEMS treated or transported more than 1,660 patients to hospitals for symptoms consistent with synthetic drug overdoses. The strain on our emergency response systems, including ambulances and emergency rooms – is significant.

The District must ensure that its laws keep up with scientific advances that allow the mass production of these dangerous chemical compounds. This legislation broadens the classification of what constitutes a prohibited synthetic drug and will allow law enforcement and prosecutors to go after the drug dealers who are bringing these deadly drugs into our communities.

If you have any questions on this matter, please contact Kevin Donahue, Deputy Mayor for Public Safety and Justice at (202) 286-5028.

Sincerely,

Muriel Bowser

Chairman Phil Mendelson
at the request of the Mayor

A BILL

IN THE COUNCIL OF THE DISTRICT OF COLUMBIA

To amend, on a temporary basis, the District of Columbia Uniform Controlled Substances Act of 1981 to add certain classes and substances to the list of Schedule I controlled substances.

BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this Act may be cited as the "Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2018".

Sec. 2. The District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-901.01 *et seq.*), is amended as follows:

(a) Section 102(27) (D.C. Official Code§ 48-901.02(27)) is amended as follows:

(1) Strike the phrase "as used in section 204(3) and section 206(1)(D)" and insert the phrase "as used in section 204(3), (5), and (6) and section 206(1)(D)" in its place.

(2) Strike the phrase "As used in section 204(3)" and insert the phrase "As used in section 204(3), (5), and (6)" in its place.

(b) Section 204 (D.C. Official Code § 48-902.04) is amended as follows:

(1) Paragraph (3) is amended as follows:

(A) The lead-in language is amended by striking the phrase "(for purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers)".

(B) New subparagraphs (G-i) through (G-xxii) are added to read as follows:

"(G-i) 25I-NBOMe (also known 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine);

"(G-ii) 25B-NBOMe (also known as 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);

"(G-iii) 25C-NBOMe (also known as 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);

"(G-iv) 5-APB (also known as 1-(benzofuran-5-yl)propan-2-amine);

"(G-v) 5-APDB (also known as 1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine);

"(G-vi) 6-APB (also known as 1-(1-benzofuran-6-yl)propan-2-amine);

"(G-vii) 6-APDB (also known as l-(2,3-dihydrobenzofuran-6-yl)propan-2-amine);

"(G-viii) 3-methoxy-PCE (also known as N-ethyl-1-(3-methoxyphenyl)cyclohexanamine);

"(G-ix) 3-methoxy-PCP (also known as 1-[1-(3-methoxyphenyl)cyclohexyl]piperidine);

"(G-x) 4-methoxy-PCP (also known as 1-[1-(4-

methoxyphenyl)cyclohexyl]piperidine);

"(G-xi) 5-MeO-DALT (also known as N,N-diallyl-5-methoxytryptamine);

"(G-xii) 4-AcO-DMT (also known as 5-acetoxy-N,N-dimethyltryptamine);".

(C) A new subparagraph (M-i) is added to read as follows:

"(M-i) Methoxetamine (also known as 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone);".

(D) Subparagraph (JJ) is amended by striking the word "and".

(E) Subparagraph (KK) is amended by striking the phrase "(2C-P);" and inserting the phrase "(2C-P); and" in its place.

(F) A new subparagraph (LL) is added to read as follows:

"(LL) Cathinone;".

(2) Paragraph (5) is amended to read as follows:

"(5) As used in this paragraph, the term "synthetic cathinones" includes any material, compound, mixture, or preparation that is not otherwise listed as a controlled substance in this schedule or in Schedules II through V, is not approved by the Food and Drug Administration as a drug, and is structurally derived from or contains any quantity of the following substances, their salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:

"(A) Classified Synthetic Cathinones:

"(i) Cathinones. Any compound, other than methylnenedioxy cathinones and pyrrolidine cathinones, containing a 2-amino-1-propanone structure with substitution at the 1-position with a monocyclic ring system, with or without alkyl, alkoxyl, or halo substitutions, and a substitution at the nitrogen atom by an alkyl group, cycloalkyl group, or incorporation into a heterocyclic structure. Examples of this structural class include:

"(I) Mephedrone, also known as:

"(aa) 2-(methylamino)-1-(4-methylphenyl)-l-propanone;

"(bb) 4-MeMC;

"(cc) 4-Methylmethcathinone;

"(dd) 4-Methylephedrone; or

"(ee) 4-MMC;

"(II) Dimethylcathinone, also known as:

"(aa) 2-(dimethylamino)-1-phenyl-l-propanone; or

"(bb) N,N-Dimethylcathinone;

"(III) Ethcathinone, also known as:

"(aa) 2-(ethylamino)-1-phenyl-1-propanone;

"(bb) Ethylcathinone;

"(cc) N-Ethylcathinone; or

"(dd) 2-Ethylaminobuphedro;

"(IV) Buphedrone, also known as:

"(aa) 2-(methylamino)-1-phenylbutan-1-one; or

"(bb) MABP;

"(V) 3,4-DMMC, also known as:

"(aa) 1-(3,4-dimethylphenyl)-2-(methylamino)-1 propanone; or

"(bb) 3,4-Dimethylmethcathinone;

"(VI) EMC, also known as:

"(aa) 1-(4-ethylphenyl)-2-(methylamino)propan-1- one;

"(bb) 4-EMC; or

"(cc) 4-Ethylmethcathinone;

"(VII) Fluoromethcathinone (also known as 1-(4-fluorophenyl)-2-(methylamino) propan-1-one);

"(VIII) 3-FMC, also known as:

"(aa) 3-fluoro-N-methylcathinone); or

"(bb) 1-(3-fluorophenyl)-2-(methylamino)propan-1- one;

"(IX) 4-FMC, also known as:

"(aa) 1-(4-fluorophenyl)-2-(methylamino)propan-1- one;

"(bb) 4-fluoro-N-methylcathinone; or

"(cc) Flephedrone;

"(X) 4-MeBP, also known as:

"(aa) 2-(methylamino)-1-(4-methylphenyl)-1-butanone;

"(bb) 4-Methylbuphedrone;

"(cc) 4-methyl BP; or

"(dd) 4-MeMABP

"(XI) 3-MEC, also known as:

"(aa) 2-(ethylamino)-1-(m-tolyl)propan-l-one; or

"(bb) 3-Methyl-N-ethylcathinone;

"(XII) 4-MEC, also known as:

"(aa) 2-(ethylamino)-1-(4-methylphenyl)-1-propanone; or

"(bb) 4-Methyl-N-ethylcathinone;

"(XIII) 3-MMC, also known as:

"(aa) 2-(methylamino)-1-(3-methylphenyl)-1-propanone;

"(bb) 3-methyl MS; or

"(cc) 3-Methylmethcathinone;

"(XIV) Methedrone (also known as l-(4-methoxyphenyl)- 2-(methylamino)-1-propanone); or

"(XV) Pentedrone (also known as 2-(methylamino)-1-phenylpentan-1-one);

"(ii) Methylenedioxy Cathinones. Any compound

containing a 2-amino-1-propanone structure with substitution at the 1-position with a monocyclic or fused polycyclic ring system and a substitution at any position of the ring system with an alkyl, haloalkyl, halogen, alkylenedioxy, or alkoxy group, whether or not further substituted at any position on the ring system to any extent. Examples of this structural class include:

"(I) 3-fluoromethylone;

"(II) Methylone, also known as

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1- propanone; or

"(bb) 3,4-Methylenedioxy-N-methylcathinone);

"(III) N-ethyl Pentylone, also known as:

"(aa) Ephylone; or

"(bb) 1-(1 ,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone;

"(IV) bk-MDDMA, also known as:

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one;

"(bb) Dimethylone;

"(cc) N,N-dimethyl-3',4'-methylenedioxycathinone;

"(dd) N,N-dimethyl-3,4-methylenedioxycathinone; or

"(ee) N,N-Dimethyl MDCATH;

"(V) Butylone, also known as 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-butanone);

"(VI) Ethylone, also known as:

"(aa) 3,4-Methylenedioxy-N-ethylcathinone; or

"(bb) MDEC; or

"(VII) Pentylone (also known as 1-(1,3-benzodioxol-5-yl)- 2-(methylamino)pentan-1-one);

"(iii) Pyrrolidine Cathinones. Any compound containing a 2-amino-1-propanone structure with substitution at the 1-position with a alkyl, cyclic or fused polycyclic ring system and a substitution at the 3-position carbon with an alkyl, haloalkyl, halogen, alkoxy or alkylenedioxy group, and a substitution at the nitrogen atom incorporation into a heterocyclic structure, with or without further halogen substitutions. Examples include:

"(I) α -PVP (also known as α -pyrrolidinopentiophenone);

"(II) α -pyrrolidinopropiophenone, also known as:

"(aa) 1-phenyl-2-(1-pyrrolidinyl)-l-propanone; or

"(bb) α -PPP;

"(III) α -PBP, also known as:

"(aa) 1-phenyl-2-(1-pyrrolidinyl)-l-butanone; or

"(bb) a-pyrrolidinobutiophenone;

"(IV) MDPBP, also known as:

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-butanone;

"(bb) 3,4-Methylenedioxy-α-Pyrrolidinobutiophenone; or

"(cc) 3,4-MDPBP

"(V) MDPPP, also known as:

"(aa) 1-(1 ,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1- propanone; or

"(bb) 3,4-Methylenedioxy- α -Pyrrolidinopropiophenone;

"(VI) MDPV, also known as:

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-l- pentanone; or

"(bb) 3,4-Methylenedioxy Pyrovalerone;

"(VII) 4-MePPP, also known as:

"(aa) 4'-methyl- α -Pyrrolidinopropiophenone;

"(bb) 4'-methyl PPP; or

"(cc) 2-(pyrrolidin-l-yl)-1-(p-tolyl)propan-1-one;

"(VIII) 4'-methyl PHP, also known as:

"(aa) 4'-methyl-α-pyrrolidinohexanophenone;

"(bb) MPHP;

"(cc) 4'-methyl-α-PHP; or

"(dd) PV4;

"(IX) Naphyrone, also known as:

"(aa) (RS)-1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one; or

"(bb) Naphpyrovalerone;

"(X) C-PVP, also known as:

"(aa) 4-Chloro-α-PVP; or

"(bb) 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one";

"(iv) Piperazine Stimulants. Any compound containing or structurally derived from a piperazine, or diethylenediamine, structure with or without substitution at one of the nitrogen atoms of the piperazine ring to any extent, including alkyl, cycloalkyl, or fused ring systems, with or without further halogen substitutions. Examples include:

"(I) BZP, also known as:

"(aa) 1-(phenylmethyl)-piperazine;

"(bb) 1-Benzylpiperazine; or

"(cc) N-Benzylpiperazine; and

"(II) TMFPP, also known as:

"(aa) 1-[3-(trifluoromethyl)phenyl]-piperazine;

"(bb) 1-(m-Trifluoromethylphenyl) piperazine; or

"(cc) 3-Trifluoromethylphenylpiperazine.

"(B) Unclassified Synthetic Cathinones:

"(i) Aminorex (also known as (RS)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine);

"(ii) α-ET, also known as:

"(I) α-ethyl-lH-indole-3-ethanamine;

"(II) α-ethyltryptamine; or

"(III) 3-Indolybutylamine;

"(iii) α-MT, also known as:

"(I) α-methyl-lH-indole-3-ethanamine; or

"(II) α-methyltryptamine;

"(iv) EMA, also known as:

"(I) N-ethyl-α-methyl-benzeneethanamine; or

"(II) N-Ethylamphetamine;

"(v) Fenethylline (also known as (RS)-1,3-dimethyl- 7-[2-(1-bpphenylpropan-2-ylamino)ethyl]purine-2,6-dione);

"(vi) N-hydroxy MDA, also known as:

"(I) MDOH;

"(II) N-hydroxy-α-methyl-1,3-benzodioxole-5-ethanamine; or

"(III) N-Hydroxy-3,4-methylenedioxyamphetamine;

"(vii) N,N-DMA, also known as:

"(I) N,N, α-trimethyl-benzeethanamine;

"(II) N,N-Dimethylamphetamine;

"(III) Dimetamfetamine; or

"(III) Metrotonin.".

(3) A new paragraph (6) is added to read as follows:

"(6) Synthetic cannabimimetic agents (also known as "synthetic cannabinoids"), which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:

"(A) Classified Synthetic Cannabimimetic Agents:

"(i) Adamantanoylindoles: Any compound containing or structurally derived from an adamantanyl-(lH-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, l-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples include:

"(I) AB-001, also known as:

"(aa) (1s,3s)-adamantan-1-yl(l-pentyl-lH-indol-3-yl)methanone; or

"(bb) JWH 018 adamantyl analog; and

"(II) AM-1248, also known as:

"(aa) [1-[(1-methyl-2-piperidinyl)methyl]-lH-indol-3-yl]tricyclo[3.3.1.13,7]dec-1-yl-methanone; or

"(bb) AM1248;

"(ii) Benzimidazole Ketone: Any compound containing or structurally derived from (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, l-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1- methoxy-3-methyl-1-oxobutan-2-yl, l-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Benzimidazole Ketones include:

"(I) FUBIMINA, also known as:

"(aa) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone; or

"(bb) AM2201 benzimidazole analog; and

"(II) JWH-018 benzimidazole analog, also known as:

"(cc) naphthalen-1-yl(1-pentyl-1H-

benzo[d]imidazol-2-yl)methanone; or

"(dd) BIM-018;

"(iii) Benzoylindoles: Any compound containing or structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or(tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples include:

"(I) AM-630, also known as:

"(aa) [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone;

"(bb) AM630; or

"(cc) Iodopravadoline;

"(II) AM-661 (also known as 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole);

"(III) AM-679, also known as:

"(aa) (2-iodophenyl)(1-pentyl-1H-indol-3 yl)methanone; or

"(bb) AM679;

"(IV) AM-694, also known as:

"(aa) [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone;

"(bb) l-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; or

"(cc) AM694;

"(V) AM-1241, also known as:

"(aa) (2-iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-lH-indol-3-yl)methanone; or

"(bb) AM1241;

"(VI) AM-2233, also known as:

"(aa) (2-iodophenyl)[l-[(l-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-methanone; or

"(bb) AM2233;

"(VII) RCS-4, also known as:

"(aa) (4-methoxyphenyl)(l-pentyl-IH-indol-3-yl)methanone; or

"(bb) SR-19; and

"(VIII) WIN 48,098, also known as:

"(aa) (4-methoxyphenyl)[2-methyl]-1-[2-(4-morpholinyl)ethyl]-lH-indol-3-yl]-methanone; or

"(bb) "Pravadoline";

"(iv) Carbazole Ketone: Any compound containing or structurally derived from (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-

piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon ofthe methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1- methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples include EG-018 (also known as naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone);

"(v) Indazole Amide: Any compound containing or structurally derived from 3-carboxamide-1H-indazoles, whether or not substituted inthe indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen. Examples include:

"(I) AB-CHMINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

"(II) AB-FUBINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide);

"(III) AB-PINACA (also known asN-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide);

"(IV) 5F AB-PINACA, also known as:

"(aa) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or

"(bb) 5-fluoro AB-PINACA;

"(V) ADB-FUBINACA (also known as N-(l-amino-3,3- dimethyl-1-oxobutan-2-yl)-l-(4-fluorobenzyl)-1-H-indazole-3-carboxamide);

"(VI) ADB-PINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide);

"(VII) 5F ADB-PINACA, also known as:

"(aa) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or

"(bb) 5-fluoro ADB-PINACA;

"(VIII) FUB-AMB, also known as:

"(aa) methyl (l-(4-fluorobenzyl)-lH-indazole-3-carbonyl)-L-valinate;

"(bb) AMB-FUBINACA; or

"(cc) MMB-FUBINACA;

"(IX) 5-fluoro-AMB (also known as (S)- methyl 2- (1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate);

"(X) MAB-CHMINACA (also known as N-(1-amino-3,3- dimethyl-1-oxobutan-2-yl)-l-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

"(XI) MMB CHMINACA, also known as:

"(aa) methyl (S)-2-(l-(cyclohexylmethyl)-lH-indole-3-carboxamido)-3,3-dimethylbutanoate; or

"(bb) MDMB-CHMICA;

"(XII) 5F MN-18, also known as:

"(aa) 1-(5-fluoropentyl)-N-1-naphthalenyl-1H-indazole-3-carboxamide; or

"(bb) 5-fluoro MN-18;

"(XIII) 5F-APINACA, also known as:

"(aa) 5-fluoro-APINACA

"(bb) 5F-AKB-48;

"(cc) 5F-AKB48;

"(dd) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; or

"(ee) N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); and

"(XIV) APINACA, also known as:

"(aa) AKB-48;

"(bb) AKB48;

"(cc) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H- indazole-3-carboxamide; or

"(dd) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;

"(vi) Cyclohexylphenols: Any compound containing or structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-

morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent. Examples include:

"(I) CP 47,497 (also known as 2-[(1S,3R)-3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol);

"(II) CP 47,497 C8 homologue, also known as:

"(aa) rel-2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol; or

"(bb) Cannabicyclohexanol;

"(III) CP 55,490;

"(IV) CP 55,940(also known as 5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol); and

"(V) CP 56,667;

"(vii) Cyclopropanoylindoles: Any compound containing or structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent. Cyclopropanoylindoles include cyclopropylmethanone indoles, as well as other cycloalkanemethanones, whether or not substituted at the nitrogen atom on the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cycloalkane ring to any extent. Examples of this structural class include:

"(I) A-796,260, also known as:

"(aa) [l-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or

"(bb) A-796260;

"(II) A-834,735, also known as:

"(aa) [l-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or

"(bb) A-834735;

"(III) AB-034 (also known as [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone);

"(IV) UR-144 (also known as 1-pentyl-3-(2, 2, 3,3-tetramethylcyclopropoyl)indole);

"(V) 5-bromo-UR-144, also known as:

"(aa) [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or

"(bb) UR-144 N-(5-bromopentyl) analog;

"(VI) 5-chloro-UR-144, also known as:

"(aa) l-(5-chloropentyl)-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole; or

"(bb) 5Cl-UR-144;

"(VII) XLRll, also knownas:

"(aa) 1-(5-fluoropentyl)-3-(2,2,3, 3-tetramethylcyclopropoyl)indole;

"(bb) 5-FUR-144; or

"(cc) 5-fluoro UR-144; and

"(VIII) FUB-144 (also known as (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone);

"(viii) Hexahydrodibenzopyrans: Any compound containing or structurally derived from Hexahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, except where contained in cannabis or cannabis resin;

"(ix) Indazole Ester (also known as Carboxylate indazole): Any compound containing or structurally derived from 3-carboxylate-indazoles, whether or not substituted in the indazole ring to any extent or substituted to any degree on the carboxylate, whether or not substituted to any extent in the indazole ring or on the carboxylate oxygen. Examples of indazole esters include 5-fluoro SDB-005, also known as:

"(I) naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate; or

"(II) 5F SDB-005;

"(x) Indole Amides: Any compound containing or structurally derived from or containing a 1H-Indole-3-carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,

3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole amides include:

"(I) Adamantylamidoindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide structure, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;

"(II) Adamantylindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the adamantyl ring to any extent;

"(III) 5F ABICA, also known as:

"(aa) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-lH-indole-3-carboxamide;

"(bb) N-(l-amino-3-methyl-1-oxobutan-2-yl)-1-(5- fluoropentyl)-1H-indole-3-carboxamide; or

"(cc) 5-fluoro ABICA;

"(IV) ADBICA (also known as N-(l-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide));

"(V) 5F-ADBICA, also known as:

"(aa) N-(l-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-lH-indole-3-carboxamide; or

"(bb) 5-fluoro-ADBICA;

"(VI) NNEl (also known as N-(naphthalen-l-yl)-1-pentyl-lH-indole-3-carboxamide);

"(VII) 5F-NNE1, also known as:

"(aa) 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-lH-indole-3-carboxamide); or

"(bb) 5-fluoro-NNEl

"(VIII) SDB-006 (also known as N-benzyl-1-pentyl-lH-indole-3-carboxamide);

"(IX) 5F-SDB-006, also known as:

"(aa) N-benzyl-1-(5-fluoropentyl)-lH-indole-3-carboxamide); or

"(bb) 5-fluoro-SDB-006;

"(X) 2NE1, also known as:

"(aa) APICA;

"(bb) JWH 018 adamantyl carboxamide; or

"(cc) l-pentyl-N-tricyclo[3.3.l.l3,7]dec-1-yl-1H-indole-3-carboxamide;

"(XI) STS-135, also known as:

"(aa) l-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-lH-indole-3-carboxamide;

"(bb) N-adamantyl-l-fluoropentylindole-3-Carboxamide;

"(cc) 5F-APICA; or

"(dd) 5-fluoro-APICA;

"(XII) SDB-006 (also known as N-benzyl-1-pentyl-lH-indole-3-carboxamide); and

"(XIV) 5-fluoro-MDMB-PICA (also known as N-[[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester);

"(xi) lndole Esters: Any compound containing or structurally derived from a lH-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, l-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, l-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Esters may also be referred to as Quinolinylindolecarboxylates. Indole esters include:

"(I) Quinolinyl ester indoles, or any compound containing or structurally derived from Quinolinyl ester indoles, being any compound containing or structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent;

"(II) BB-22, also known as:

"(aa) 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;

"(bb) quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; or

"(cc) QUCHIC;

"(III) FDU-PB-22 (also known as naphthalen-1-yl 1-(4-fluorobenzyl)-lH-indole-3-carboxylate);

"(IV) FUB-PB-22, also known as:

"(aa) 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylic acid, 8-quinolinyl ester; or

"(bb) Quinolin-8-yl 1-(4-fluorobenzyl)-lH-indole-3-carboxylate;

"(V) NM2201, also known as:

"(aa) naphthalen-1-yl 1-(5-fluoropentyl)-IH-indole-3-carboxylate; or

"(bb) CBL-2201;

"(VI) PB-22, also known as:

"(aa) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid;

"(bb) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;

"(cc) 8-Quinolinyl 1-pentyl-1H-indole-3-carboxylate; or

"(dd) "QUPIC"; and

"(VII) 5F-PB-22, also known as:

"(aa) 1I-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;

"(bb) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;

"(cc) 8-Quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;

"(dd) 5-fluoro-PB-22; or

"(ee) 5-fluoro QUPIC;

"(xii) Naphthoylindoles: Any compound containing or structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, I-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212,

JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55-212. Napthoylindoles also include:

"(I) AM-2201 (also known as (l-(5-fluoropentyl)-3-(1-naphthoyl)indole); and

"(II) WIN 55,212-2, also known as:

"(aa) (R)-(+)-[2,3-dihydro-5-methyl-3- (4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or

"(bb) [2,3-Dihydro-5-methyl- 3-(4-morpholinylmethyl)pyrrolo[(l,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone);

"(xiii) Naphthoylnaphthalenes: Any compound containing or structurally derived from naphthalene-1-yl-(naphthalene-l-yl) methanone with substitutions on either of the naphthalene rings to any extent. Naphthoylnaphthalenes include CB-13, also known as CRA-13 or l-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone;

"(xiv) Naphthoylpyrroles: Any compound containing or structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-

244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;

"(xv) Naphthylamidoindoles: Any compound containing or structurally derived from a N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted to any extent in the indole ring or the naphthyl ring;

"(xvi) Naphthylmethyl Indoles: Any compound containing or structurally derived from 1H-indol-3-yl-(1-naphthyl)methane structure, also known as napthylmethylindoles, with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent. Examples of this structural class include:

"(I) JWH-175 (also known as 3-(1-naphthalenylmethyl)-1-pentyl-1H-indole);

"(II) JWH-184 (also known as 3-[(4-methyl-1-naphthalenyl)methyl]-1-pentyl-1H-indole);

"(III) JWH-185 (also known as 3-[(4-methoxy-1-naphthalenyl)methyl]-1-pentyl-1H-indole);

"(IV) JWH-192 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethane);

"(V) JWH-194 (also known as 2-methyl-1-pentyl-1H-

indol-3-yl-(4-methyl-1-naphthyl)methane);

"(VI) JWH-195 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethane);

"(VII) JWH-196 (also known as 2-methyl-3-(1-naphthalenylmethyl)-1-pentyl-lH-Indole);

"(VIII) JWH-197 (also known as 2-methyl-1-pentyl-lH-indol-3-yl-(4-methoxy-1-naphthyl)methane); and

"(IX) JWH-199 (also known as (l-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethane);

"(xvii) Naphthylmethylindenes: Any compound containing or structurally derived from a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples include:

"(I) JWH-171;

"(II) JWH-176 (also known as 1-[(E)-(3-pentyl-lH-inden-1-ylidene)methyl]-naphthalene); and

"(III) JWH-220;

"(xviii) Phenylacetylindoles: Any compound containing or structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the

indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including: JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, SR-18, and Cannabipiperidiethanone (also known as 2-(2-methoxyphenyl)-1-[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-ethanone);

"(xix) Quinolinoyl pyrazole: Any compound containing or structurally derived from Quinolinoyl pyrazole carboxylate (also known as Quinolinyl fluoropentyl fluorophenyl pyrazole carboxylate);

"(xx) Tetrahydrobenzochromen: Any compound containing or structurally derived from (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Includes tetrahydrodibenzopyrans, or any compound containing or structurally derived from tetrahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, but does not include tetrahydrodibenzopyrans that are contained in cannabis or cannabis resin. Examples of this structural class include:

"(I) AM-087 (also known as (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)- 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);

"(II) AM-411 (also known as (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);

"(III) HU-210, also known as:

"(aa) 3-(l,l'-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;

"(bb) [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol;

"(cc) l,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; or

"(dd) 1,l-dimethylheptyl-ll-hydroxy-delta8-tetrahydrocannabinol;

"(IV) HU-211, also known as:

"(aa) 3-(1,1-dimethylheptyl)-6aS,7,10,10aS-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;

"(bb) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

"(cc) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or

"(dd) "Dexanabinol";

"(V) HU-243, also known as:

"(aa) (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol; or

"(bb) 3-dimethylheptyl-11-hydroxyhexahydrocannabinol;

"(VI) JWH-051 (also known as (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol);

"(VII) JWH-133 (also known as(6aR,10aR)-3-(l,l-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran); and

"(VIII) JWH-359 (also known as (6aR,10aR)- 1-methoxy-6,6,9-trimethyl- 3-[(2R)-l,l,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene);

"(xxi) Δ 8-Tetrahydrocannabinol: Any compound containing or structurally derived from 11-hydroxy- Δ 8-tetrahydrocannabinol structure, also known as dibenzopyrans, with further substitution on the 3-pentyl group by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkyethyl, 1-(n-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group;

"(xxii) Tetramethylcyclopropane-thiazole carboxamides: Any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent, including the group Tetramethylcyclopropyl thiazoles, or any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not

746 substituted in the tetramethylcyclopropyl ring to any extent. Tetramethylcyclopropane-
747 thiazole carboxamides also include A-836,339, also known as:
748 "(I) [N(Z)]-N-[3-(2-methoxyethyl)-4,5-dimethyl-2(3H)-
749 thiazolylidene]-2,2,3,3-tetramethyl-cyclopropanecarboxamide;
750 "(II) N-[3-{2-Methoxyethyl)-4,5-dimethyl- 1 ,3-thiazol-
751 2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropanecarboxamide: or
752 "(III) A-836339;
753 "(xxiii) Benzodihydropyrans: Any compound containing or
754 structurally derived from benzodihydropyrans, by substitution on the benzyl ring by
755 hydroxy, alkyl, haloalkyl, alkoxy, cycloalkyl, alkene, haloalkene, cycloalkane, or by
756 substitution on the pyran ring by alkyl, cycloalkyl, cycloalkene, or cycloalkoxy group to
757 any extent. Examples of this structural class include:
758 "(I) AM-855 (also known as (4aR,12bR)-8-hexyl-2,5,5-
759 trimethyl-1 ,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol);
760 "(II) AM-905 (also known as (6aR,9R,10aR)-3-[(E)-
761 hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9, 10,10a-
762 hexahydrobenzo[c]chromen-1-ol);
763 "(III) AM-906 (also known as (6aR,9R,10aR)-3-[(Z)-
764 hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-
765 hexahydrobenzo[c]chromen-1-ol);
766 "(IV) AM-2389 (also known as (6aR,9R,10aR)-3-(1-
767 hexylcyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-l,9
768 diol); and

"(V) JWH-057 (also known as (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran);

"(xxiv) Benzimidazole Ketone: Any compound containing or structurally derived from [1H-indazol-3-yl](1-naphthyl)methanone structure with or without substitution at either nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples of this structural class include:

"(I) THJ-2201 (also known as [1-(5-Fluoropentyl)-1H-indazol-3-yl](1-naphthyl)methanone); and

"(II) THJ-018 (also known as 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone);

"(B) Unclassified Synthetic Cannabimimetic Agents:

"(i) AM-356, also known as:

"(I) AM356;

"(II) arachidonyl-1'-hydroxy-2'-propylamide;

"(III) N-(2-hydroxy-1R-methylethyl)-5Z,8Z,11Z,

14Z-eicosatetraenamide;

"(IV) (R)-(+)-Arachidonyl-1'-Hydroxy-2'-Propylamide;

"(V) Methanandamide; or

"(VI) R-1 Methanandamide;

"(ii) BAY38-7271 (also known as (-)-(R)-3-(2-Hydroxymethylindanyl -4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate);

"(iii) CP 50,556-1, also known as:

"(I) 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a, 7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;

"(II) [(6S,6aR,9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-; octahydrophenanthridin-1-yl] acetate;

"(III) [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9, 10, 10a-octahydrophenanthridin-1-yl]acetate; or

"(IV) "Levonantradol";

"(iv) HU-308 (also known as (91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol);

"(v) HU-331 (also known as 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione);

"(vi) JTE-907 (also known as N-(benzol[1,3]dioxol-5-

ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide);

"(vii) Mepirapim (also known as (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) Methanone);

"(viii) URB597 (also known as [3-(3-carbamoylphenyl)phenyl]-N-Cyclohexylcarbamate);

"(ix) URB602, also known as:

"(I) [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or

"(II) cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;

"(x) URB754 (also known as 6-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one); and

"(xi) URB937 (also known as 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl Cyclohexylcarbamate).".

(4) A new paragraph (7) is added to read as follows:

"(7) Synthetic opioids, which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of, the following synthetic substances, their salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:

"(A) Classified Synthetic Opioids:

"(i) Fentanyls: Any compound, other than

carbomethoxyfentanyls, containing or structurally derived from N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide, whether or not substituted on the methanone group with an alkyl, alkene, halo, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, cyanoalkyl, hydroxyalkyl, furanyl, or alkoxy, and whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Examples of fentanyls include:

"(I) Fentanyl (also known as N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide);

"(II) Furanylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide);

"(III) Acetylfentanyl (also known as N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide);

"(IV) Acrylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]prop-2-enamide);

"(V) Parafluorofentanyl, also known as:

"(aa) 4-fluorofentanyl; or

"(bb) N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide;

"(VI) Butyryl fentanyl also known as:

"(aa) Butyr fentanyl;

"(bb) NIH 10486; or

"(cc) N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide; and

"(VII) para-Fluorobutyryl fentanyl, also known as:

"(aa) 4-FPF;

"(bb) p-FBF;

"(cc) 4-Fluorobutyryl fentanyl;

"(dd) p-Fluorobutyryl fentanyl; or

"(ee) N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide);

"(ii) Carbomethoxyfentanyls: Any compound containing or structurally derived from 4-((1-oxopropyl)-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester, whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Carbomethoxyfentanyls include:

"(I) Carfentanil, also known as:

(aa) 4-Carbomethoxy Fentanyl;

(bb) 4-carbomethoxy Fentanyl; or

(cc) 4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylic acid, methyl ester;

"(II) Norcarfentanil (also known as: 4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester;

"(III) N-methyl Norcarfentanil, also known as:

(aa) N-methyl Carfentanil;

(bb) N-methyl Norremifentanil;

(cc) N-methyl Remifentanil; or

(dd) 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester;

"(iii) Benzamides: Any compound containing or structurally derived from 3,4-Dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide, whether or not substituted on the phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group, and whether or not substituted with an alkyl or hydrogen on the nitrogen of the amide, and whether or not substituted on the nitrogen of the amide with an alkyl, cycloalkyl, tertiary amine, or combination thereof. Benzamides include:

"(I) U-47700 (also known as 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide); and

"(II) AH-7921 (also known as 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide).

"(B) Unclassified Synthetic Opioids:

"(I) W-18 (also known as 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]2-piperidinylidene]benzenesulfonamide).";

"(II) Sufentanil (also known as N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide).";

"(III) Alfentanil (also known as N-[1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-N-phenyl-propanamide).";

"(IV) Remifentanil (also known as 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid, methyl ester).";

"(V) Lofentanil (also known as methyl (3R,4S)-3-methyl-1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate)."

"(VI) Benzyl Carfentanil (also known as methyl 1-benzyl-4-(N-phenylpropionamido)piperidine-4-carboxylate);

"(VII) N-methyl-Norcarfentanil (also known as 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester).".

(c) Section 208(a)(7) (D.C. Official Code§ 48-902.08(a)(7)) is repealed.

Sec. 3. Fiscal impact statement.

The Council adopts the fiscal impact statement of the Budget Director as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).

Sec. 4. Effective date.

(a) This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(l)), and publication in the District of Columbia Register.

(b) This act shall expire after 225 days of its having taken effect.

GOVERNMENT OF THE DISTRICT OF COLUMBIA
Office of the Attorney General

ATTORNEY GENERAL
KARL A. RACINE

Legal Counsel Division

PRIVILEGED AND CONFIDENTIAL
ATTORNEY-CLIENT COMMUNICATION

MEMORANDUM

TO: **Alana Intrieri**
Executive Director
Office of Policy and Legislative Affairs

FROM: **Janet M. Robins**
Deputy Attorney General
Legal Counsel Division

DATE: **September 25, 2018**

SUBJECT: **Legal Sufficiency Review of Draft Revised Synthetics Abatement and Full Enforcement Drug Control Emergency, Temporary, and Permanent Amendment Acts (AE-18-515)**

On September 24, 2018, you asked us for an expedited legal sufficiency review of the above bill, which amends the District of Columbia Uniform Controlled Substances Act of 1981 ("Controlled Substances Act").[1] The bill incorporates synthetic cathinones, synthetic cannabinoids, and synthetic opioids into Schedule I of the Act,[2] and supplements the existing Schedule I list of hallucinogens. It also standardizes the Schedule I language concerning isomers.[3] Most provisions in Schedule I refer simply to "isomers," but subsection (3) of Schedule I states that "for the purposes of *this [subsection] only*, the term 'isomer' includes the optical, position, and

---

[1] The Controlled Substances Act was effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code 48-902.01 *et seq.* (2012 Repl. and 2015 Supp.)).

[2] Schedule I is section 204 of the Controlled Substances Act (D.C. Official Code § 48-902.04 (2012 Repl. and 2015 Supp.)). It is designed for substances that have a high potential for abuse and have no accepted medical use in treatment in the United States or the District. *See* D.C. Official Code § 48-902.03 (2012 Repl.).

[3] An isomer is "one of two or more compounds, radicals, or ions that contain the same number of atoms of the same elements but differ in structural arrangement and properties." MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY 664 (11th ed. 2004).

geometric isomers" (emphasis added). To avoid confusion, and undermine any inference that *other* references to "isomer" are not so expansive, the bill would strike this expanded language from subsection (3).

This bill, which draws heavily from a bill this office previously introduced,[4] incorporates the expertise of the Department of Forensic Sciences. We are not chemists, and we defer to the Department's extensive knowledge of this subject. The draft bill also incorporates some technical and minor substantive revisions this office recommended.

The draft bill is legally sufficient. If you have any questions, please contact Josh Turner, Assistant Attorney General, at 442-9834, or me at 724-5524.

JMR/jat

[4] *See* Revised Synthetics Abatement and Full Enforcement Drug Control Amendment Act of 2017, as introduced on Dec. 11, 2017 (Bill 22-628).

GOVERNMENT OF THE DISTRICT OF COLUMBIA
Office of the Attorney General

ATTORNEY GENERAL
KARL A. RACINE

Legal Counsel Division

MEMORANDUM

TO: Lolita S. Alston
Director
Office of Legislative Support

FROM: Janet M. Robins
Deputy Attorney General
Legal Counsel Division

DATE: September 25, 2018

SUBJECT: Legal Sufficiency Review of Draft Revised Synthetics Abatement and Full Enforcement Drug Control Emergency, Temporary, and Permanent Amendment Acts
(AE-18-515)

This is to Certify that this Office has reviewed the above-referenced draft legislation and found it to be legally sufficient. If you have any questions in this regard, please do not hesitate to call me at 724-5524.

Janet M. Robins